HANGZHOU, China, July 4, 2024
/PRNewswire/ -- Giant Biogene, Global Leader in Recombinant
Collagen[1] announced
the launch of its latest super premium skincare line, Vpro,
specifically designed to address advanced anti-wrinkle, firming,
and lifting needs. Vpro combines Vlock 4D recombinant collagen with
Bosein and polypeptide to deliver holistic, multi-dimensional skin
rejuvenation.
Renowned for its pioneering work in recombinant
collagen[1], Giant
Biogene continues to lead in developing cutting-edge solutions that
address the cosmetic industry's complex challenges. Their latest
product line VPro, integrates their most recent breakthrough, Vlock
4D recombinant collagen, signaling a notable advance in
collagen-based anti-aging treatments.
A recent study from Giant Biogene's R&D facility outlines
Vlock 4D recombinant collagen's three primary advantages:
1. Replenishing cellular energy and stimulating cell vitality
at the core
ATP, crucial for cell survival, acts as the cellular energy
center[2]. The relative
fluorescence intensity of the mitochondrial membrane potential in
human fibroblasts is 313.92% at the tested concentration of the
Vlock 4D recombinant collagen[3].
2. Promoting the growth of nine types of collagen and various
intercellular matrices
The assay results for Vlock 4D recombinant collagen raw material
demonstrated enhanced gene expression of collagen types I, III, IV,
V, VI, VII, XIII, XVI, and XVII compared to the control group.
Notably, the gene expression of collagen type III increased by
276.46%[3].
Additionally, the recombinant collagen significantly boosts the
gene expression of Filaggrin (FLG), Loricrin (LOR) and tight
junction protein ZO-1[3].
3. Enabling effective transdermal absorption and rapid
penetration into the dermal layer
Employing Vlock 4D recombinant collagen as a test sample, the
transdermal absorption test demonstrated successful penetration
from the epidermis to the dermis at 8 and 24 hours. Supported by
Giant Biogene's patented transdermal technology[4], these results provide a robust
foundation for the transdermal absorption of collagen.
Proven results: Increased dermal density and enhanced
collagen strength
In a study involving thirty-one subjects, the use of a product
containing Vlock 4D recombinant collagen over four consecutive
weeks demonstrated a significant increase in dermal density when
compared to the pre-use period. Measurements taken after 15
minutes, 2 weeks, and 4 weeks showed continuous improvement, with
the dermal density increase at 4 weeks reaching 20.3%, indicating a
substantial enhancement in collagen strength[5]. These experimental results
validate the effectiveness of products containing Vlock 4D
recombinant collagen.
1. Source: Euromonitor
International (Shanghai) Limited, based on 2023 revenue.
Recombinant collagen companies are defined as those capable of
independently developing, producing, and selling recombinant
collagen raw materials, or using their own recombinant collagen as
the primary raw material to produce and sell end products.
Recombinant collagen is created using recombinant DNA technology,
which involves the genetic manipulation and/or modification of
genes that encode required human collagen proteins. The process
uses plasmids or viral vectors to introduce target genes into
appropriate host cells (such as bacteria, yeast, or other
eukaryotic cells), which are then expressed and translated into
collagen or collagen-like peptides. The final product is prepared
through extraction and purification, and includes recombinant human
collagen, recombinant human-like collagen, and recombinant
collagen-like proteins. Research completed in March 2024.
2. Recombinant collagen companies are defined as those capable of
independently developing, producing, and selling recombinant
collagen raw materials, or using their own recombinant collagen as
the primary raw material to produce and sell end products.
Recombinant collagen is created using recombinant DNA technology,
which involves the genetic manipulation and/or modification of
genes that encode required human collagen proteins. The process
uses plasmids or viral vectors to introduce target genes into
appropriate host cells (such as bacteria, yeast, or other
eukaryotic cells), which are then expressed and translated into
collagen or collagen-like peptides. The final product is prepared
through extraction and purification processes, and includes
recombinant human collagen, recombinant humanized collagen, and
recombinant collagen-like proteins. Research completed in March
2024, Du Cijie, Chen Baodan, Wang Mengfei, Guo Jingyi, Liu Xingguo.
Mitochondria and Cell Fate Regulation. Chinese Journal of Cell
Biology, 2024, 46 (01): 79-89.
3. Derived from the results of Vlock 4D recombinant collagen raw
material testing by an authoritative third-party professional
testing organization
4. Patent numbers: ZL 202210102466.7, ZL 202210100932.8
5. Data from a third-party efficacy testing organization; involving
31 women aged 36 to 50 years who used the product for 28 days.
Note: Experimental data is for reference only, and actual effects
may vary individually
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/giant-biogene-launches-new-brand-vpro-featuring-vlock-4d-recombinant-collagen-for-cellular-anti-aging-302189433.html
SOURCE Hangzhou Giant Biogene Technology Co.,Ltd